A 4 Week Study of the Safety, Tolerability, and Pharmacodynamics of ShK-186 (Dalazatide) in Active Plaque Psoriasis
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to examine safety outcomes in active plaque psoriasis
patients after systemic administration of dalazatide. Clinical outcome measures will also be
assessed.